Literature DB >> 14517945

Molecular pathology of NEU1 gene in sialidosis.

Volkan Seyrantepe1, Helena Poupetova, Roseline Froissart, Marie-Thérèse Zabot, Irène Maire, Alexey V Pshezhetsky.   

Abstract

Lysosomal sialidase (EC 3.2.1.18) has a dual physiological function; it participates in intralysosomal catabolism of sialylated glycoconjugates and is involved in cellular immune response. Mutations in the sialidase gene NEU1, located on chromosome 6p21.3, result in autosomal recessive disorder, sialidosis, which is characterized by the progressive lysosomal storage of sialylated glycopeptides and oligosaccharides. Sialidosis type I is a milder, late-onset, normosomatic form of the disorder. Type I patients develop visual defects, myoclonus syndrome, cherry-red macular spots, ataxia, hyperreflexia, and seizures. The severe early-onset form, sialidosis type II, is also associated with dysostosis multiplex, Hurler-like phenotype, mental retardation, and hepatosplenomegaly. We summarize information on the 34 unique mutations determined so far in the sialidase gene, including four novel missense and one novel nonsense mutations found in two Czech and two French sialidosis patients. The analysis of sialidase mutations in sialidosis revealed considerable molecular heterogeneity, reflecting the diversity of clinical phenotypes that make molecular diagnosis difficult. The majority of sialidosis patients have had missense mutations, many of which have been expressed; their effects on activity, stability, intracellular localization, and supramolecular organization of sialidase were studied. A structural model of sialidase allowed us to localize mutations in the sialidase molecule and to predict their impact on the tertiary structure and biochemical properties of the enzyme. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517945     DOI: 10.1002/humu.10268

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  41 in total

1.  Sialidosis type I with neoplasms in siblings: the first clinical cases.

Authors:  Yohsuke Yagi; Akira Machida; Shuta Toru; Takayoshi Kobayashi; Toshiki Uchihara
Journal:  Neurol Sci       Date:  2010-08-13       Impact factor: 3.307

Review 2.  Progressive myoclonic epilepsies: review of clinical, molecular and therapeutic aspects.

Authors:  Luis Felipe Mendonça de Siqueira
Journal:  J Neurol       Date:  2010-07-01       Impact factor: 4.849

Review 3.  Sialidase significance for cancer progression.

Authors:  Taeko Miyagi; Kohta Takahashi; Keiko Hata; Kazuhiro Shiozaki; Kazunori Yamaguchi
Journal:  Glycoconj J       Date:  2012-05-29       Impact factor: 2.916

4.  In vivo crystallography at X-ray free-electron lasers: the next generation of structural biology?

Authors:  François-Xavier Gallat; Naohiro Matsugaki; Nathan P Coussens; Koichiro J Yagi; Marion Boudes; Tetsuya Higashi; Daisuke Tsuji; Yutaka Tatano; Mamoru Suzuki; Eiichi Mizohata; Kensuke Tono; Yasumasa Joti; Takashi Kameshima; Jaehyun Park; Changyong Song; Takaki Hatsui; Makina Yabashi; Eriko Nango; Kohji Itoh; Fasséli Coulibaly; Stephen Tobe; S Ramaswamy; Barbara Stay; So Iwata; Leonard M G Chavas
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-07-17       Impact factor: 6.237

5.  Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies.

Authors:  Yanhong Li; Hongzhi Cao; Hai Yu; Yi Chen; Kam Lau; Jingyao Qu; Vireak Thon; Go Sugiarto; Xi Chen
Journal:  Mol Biosyst       Date:  2011-01-04

6.  Effects of sialidase NEU1 siRNA on proliferation, apoptosis, and invasion in human ovarian cancer.

Authors:  Li-rong Ren; Li-ping Zhang; Shu-ying Huang; Yuan-fang Zhu; Wen-juan Li; Shan-yu Fang; Li Shen; Yan-ling Gao
Journal:  Mol Cell Biochem       Date:  2015-10-13       Impact factor: 3.396

7.  Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9.

Authors:  Trisha M Finlay; Preethi Jayanth; Schammim Ray Amith; Alanna Gilmour; Christina Guzzo; Katrina Gee; Rudi Beyaert; Myron R Szewczuk
Journal:  Glycoconj J       Date:  2010-03-06       Impact factor: 2.916

8.  Elastin peptides signaling relies on neuraminidase-1-dependent lactosylceramide generation.

Authors:  Anthony Rusciani; Laurent Duca; Hervé Sartelet; Aurore Chatron-Colliet; Hélène Bobichon; Dominique Ploton; Richard Le Naour; Sébastien Blaise; Laurent Martiny; Laurent Debelle
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

9.  Three novel beta-galactosidase gene mutations in Han Chinese patients with GM1 gangliosidosis are correlated with disease severity.

Authors:  Chi-Fan Yang; Jer-Yuarn Wu; Fuu-Jen Tsai
Journal:  J Biomed Sci       Date:  2010-09-30       Impact factor: 8.410

10.  Protective protein/cathepsin A rescues N-glycosylation defects in neuraminidase-1.

Authors:  Dongning Wang; Slava Zaitsev; Garry Taylor; Alessandra d'Azzo; Erik Bonten
Journal:  Biochim Biophys Acta       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.